Despite significant paradigm shifts in the medical management of hemophilia A with inhibitors and the expanding use of novel non-factor therapies, FVIII-based immune tolerance induction (ITI) is still the only effective means to inhibitor eradication. With the recently introduced Atlanta protocol, emicizumab prophylaxis is given in combination with 50-100 IU/kg FVIII three times a week. […]
In this plenary from the WFH 2020 Virtual Summit, Steve Kitchen, Alok Srivastava and Pierre Toulon discuss the combination of high BAT score followed by NGS-based genetic diagnosis could be the new paradigm for the primary diagnosis of inherited bleeding disorders. The WFH does not engage in the practice of medicine and under no circumstances […]
Listen to this 90-minute webinar, Setting up comprehensive care: key principles, services, and roles, presented on September 29, 2021, the first of 3 webinars in the PACT Comprehensive Care Series, designed to support healthcare providers in setting up and strengthening comprehensive care in their centres. The session was moderated by Dr. Alok Srivastava (Professor in […]
Listen to this 90-minute webinar presented on July 30, 2021, on the WFH Guidelines for the Management of Hemophilia, 3rd edition and their practical application in the Middle East. The session was moderated by Alok Srivastava (Professor in the Department of Haematology, and Head of the Centre for Stem Cell Research at the Christian Medical […]
Presents data on the reported use of factor VIII (FVIII) per country. FVIII use varies considerably, even among the wealthiest countries, and increases with economic capacity.